Influence of genetic, biological and pharmacological factors on warfarin dose in a southern Brazilian population of European ancestry

British Journal of Clinical Pharmacology

Volumn 72, Issue 3, 2011, Pages 442-450

  Botton, Mariana Rodrigues ^a   Bandinelli, Eliane ^a   Rohde, Luis Eduardo Paim ^b   Amon, Luis Carlos ^b   Hutz, Mara Helena ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

CYP2C9; CYP4F2; F2; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

AMIODARONE; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; CYTOCHROME P450 ISOENZYME; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ALGORITHM; ALLELE; ANTICOAGULATION; ARTICLE; BIOLOGICAL TRAIT; BRAZIL; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE REGIMEN; EUROPE; F2 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; PHARMACOGENETICS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT DURATION; VKORC1 GENE;

AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BRAZIL; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; STATISTICS AS TOPIC; WARFARIN;

EID: 79961134642     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03942.x     Document Type: Article

References (42)

1. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
2. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
3. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008; 25: 45-51.
4. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Clampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-78.
5. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D. Interindividual variability in sensitivity to warfarin - Nature or nurture? Clin Pharmacol Ther 2001; 70: 159-64.
6. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-19.
7. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P4502C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120: 181-86.
8. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-49.
9. Borgiani P, Ciccaci C, Forte V, Sirianni E, Novelli L, Barmanti P, Novelli G. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009; 10: 261-66.
10. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Zhang KQ, Berg RL, Burmester JK. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-12.
11. D'Ambrosio RL, D'Andrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V, Grandone E, Margaglione M. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 2004; 89: 1510-16.
12. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103: 2630-35.
13. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-31.
14. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95: 782-87.
15. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MTM, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA, Chen YT, Wen MS, Caraco Y, Achache I, Blotnick S, Muszkat M, Shin JG, Kim HS, Suarez-Kurtz G, Perini JA, Silva-Assuncao E, Andereson JL, Horne BD, Carlquist JF, Berg RL, Burmester JK, Goh BC, Lee SC, Kamali F, Sconce E, Daly AK, Wu AHB, Langaee TY, Feng H, Cavallari L, Momary K, Pirmohamed M, Jorgensen A, Toh CH, Williamson P, McLeod H, Evans JP, Weck KE, Brensinger C, Nakamura Y, Mushiroda T, Veenstra D, Meckley L, Rieder MJ, Rettie AE, Wadelius M, Melhus H, Stein CM, Schwartz U, Kurnik D, Deych E, Lenzini P, Eby C, Chen LY, Deloukas P, Motsinger-Reif A, Sagreiya H, Srinivasan BS, Lantz E, Chang T, Ritchie M, Lu LS. Estimation of the warfarin dose with clinical and pharmacogenetic data (vol 360, pg 753, 2009). N Engl J Med 2009; 361: 1613-13.
16. Miao LY, Yang J, Huang CR, Shen ZY. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63: 1135-41.
17. Perini JA, Struchiner CJ, Silva-Assuncao E, Santana ISC, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther 2008; 84: 722-28.
18. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
19. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R, Linder MW. Estimation of warfarin maintenance dose based on VKORCI (-1639 G >A) and CYP2C9 genotypes. Clin Chem 2007; 53: 1199-205.
20. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995; 56: 799-810.
21. Balding D. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7: 781-91.
22. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-92.
23. Perini JA, Struchiner CJ, Silva-Assuncao E, Suarez-Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010; 87: 417-20.
24. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-70.
25. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75: 204-12.
26. Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 2008; 64: 9-15.
27. Cho HJ, Sohn KH, Park HM, Lee KH, Choi BY, Kim S, Kim JS, On YK, Chun MR, Kim HJ, Kim JW, Lee SY. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 2007; 8: 329-37.
28. Yuan HY, Chen JJ, Lee MTM, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-51.
29. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433. doi:10.1371/journal.pgen.1000433.
30. Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahe I, Legendre C, Taillandier-Heriche E, Durand-Gasselin B, Houllier AM, Verrier P, Beaune P, Loriot MA, Siguret V. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010; 87: 57-64.
31. Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 2003; 89: 949-50.
32. Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. Ann Pharmacother 2007; 41: 1292-95.
33. Limdi N, Wadelius M, Cavallari L, Eriksson N, Crawford D, Lee M, Chen C, Motsinger-Reif A, Sagreiya H, Liu N, Wu A, Gage B, Jorgensen A, Pirmohamed M, Shin J, Suarez-Kurtz G, Kimmel S, Johnson J, Klein T, Wagner M, Consortium IWP. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-34.
34. Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004; 116: 651-56.
35. Chen LY, Eriksson N, Gwilliam R, Bentley D, Deloukas P, Wadelius M. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 2005; 106: 3673-74.
36. Visser LE, Trienekens PH, De Smet P, Vulto AG, Hofman A, van Duijn CM, Stricker BHC. Patients with an ApoE epsilon 4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 2005; 15: 69-74.
37. Gonzalez-Conejero R, Corral J, Roldan V, Ferrer F, Sanchez-Serrano I, Sanchez-Blanco JJ, Marin F, Vicente V. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost 2007; 5: 1701-06.
38. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-11.
39. Wajih N, Sane DC, Hutson SM, Wallin R. The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system - Characterization of the system in normal and warfarin-resistant rats. J Biol Chem 2004; 279: 25276-83.
40. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Halkin H, Almog S. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P4502C9. Clin Pharmacol Ther 2005; 77: 365-72.
41. Lenzini P, Grice G, Milligan P, Dowd M, Subherwal S, Deych E, Eby C, King C, Porche-Sorbet R, Murphy C, Marchand R, Millican E, Barrack R, Clohisy J, Kronquist K, Gatchel S, Gage B. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008; 6: 1655-62.
42. Sasaki T, Tabuchi H, Higuchi S, Ieiri I. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics 2009; 10: 1257-66.